CU24709B1 - Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica - Google Patents

Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica

Info

Publication number
CU24709B1
CU24709B1 CU2020000064A CU20200064A CU24709B1 CU 24709 B1 CU24709 B1 CU 24709B1 CU 2020000064 A CU2020000064 A CU 2020000064A CU 20200064 A CU20200064 A CU 20200064A CU 24709 B1 CU24709 B1 CU 24709B1
Authority
CU
Cuba
Prior art keywords
pspa1
pneumococcal
surface protein
nucleic acid
acid encoding
Prior art date
Application number
CU2020000064A
Other languages
English (en)
Other versions
CU20200064A7 (es
Inventor
Mahima Datla
Swetha Kamireddy
Narender Dev Mantena
Ramesh Venkat Matur
Rajan Sriraman
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of CU20200064A7 publication Critical patent/CU20200064A7/es
Publication of CU24709B1 publication Critical patent/CU24709B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención se refiere a un ácido nucleico que codifica la proteína de superficie neumocócica A1 (PspA1) truncada, a un constructo de expresión para la expresión de alto nivel de la proteína de superficie neumocócica A1 (PspA1) truncada y a una vacuna conjugada neumocócica que comprende al menos un polisacárido de serotipos de Streptococcus pneumoniae.</p> <p> La invención representa un avance en el campo de la ingeniería genética y la tecnología de vacunas. </p>
CU2020000064A 2018-03-01 2019-03-01 Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica CU24709B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01
PCT/IB2019/051655 WO2019167008A1 (en) 2018-03-01 2019-03-01 Expression of pneumococcal surface protein a (pspa)

Publications (2)

Publication Number Publication Date
CU20200064A7 CU20200064A7 (es) 2021-04-07
CU24709B1 true CU24709B1 (es) 2024-06-11

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000064A CU24709B1 (es) 2018-03-01 2019-03-01 Ácido nucleico que codifica la proteína de superficie neumocócica a1 (pspa1) truncada, constructo de expresión para la expresión de alto nivel de la misma y vacuna conjugada neumocócica

Country Status (20)

Country Link
US (2) US11725029B2 (es)
EP (1) EP3758746A1 (es)
JP (2) JP7334176B2 (es)
KR (1) KR102774793B1 (es)
CN (1) CN112118865B (es)
AU (1) AU2019226487B2 (es)
BR (1) BR112020017431A2 (es)
CA (1) CA3091583A1 (es)
CL (1) CL2020002246A1 (es)
CU (1) CU24709B1 (es)
EA (1) EA202092065A1 (es)
IL (1) IL277023B2 (es)
MX (1) MX2020009049A (es)
MY (1) MY204760A (es)
PH (1) PH12020551357A1 (es)
SA (1) SA520420041B1 (es)
SG (1) SG11202008124XA (es)
UA (1) UA129585C2 (es)
WO (1) WO2019167008A1 (es)
ZA (1) ZA202005414B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US8604180B2 (en) * 2004-09-09 2013-12-10 Research Institute Of Innovative Technology For The Earth DNA fragment having promoter function
KR101623999B1 (ko) 2008-06-25 2016-05-24 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
US20210009641A1 (en) 2021-01-14
JP7645946B2 (ja) 2025-03-14
SA520420041B1 (ar) 2024-03-14
CU20200064A7 (es) 2021-04-07
AU2019226487A1 (en) 2020-09-10
EP3758746A1 (en) 2021-01-06
KR20200129121A (ko) 2020-11-17
JP2021516050A (ja) 2021-07-01
CN112118865A (zh) 2020-12-22
CA3091583A1 (en) 2019-09-06
UA129585C2 (uk) 2025-06-11
IL277023B1 (en) 2025-07-01
PH12020551357A1 (en) 2021-08-23
CL2020002246A1 (es) 2021-01-15
JP2023154063A (ja) 2023-10-18
CN112118865B (zh) 2025-03-28
IL277023B2 (en) 2025-11-01
MX2020009049A (es) 2020-10-12
SG11202008124XA (en) 2020-09-29
US20230322871A1 (en) 2023-10-12
IL277023A (en) 2020-10-29
BR112020017431A2 (pt) 2021-01-19
KR102774793B1 (ko) 2025-02-27
US11725029B2 (en) 2023-08-15
ZA202005414B (en) 2022-02-23
WO2019167008A1 (en) 2019-09-06
JP7334176B2 (ja) 2023-08-28
EA202092065A1 (ru) 2020-11-19
MY204760A (en) 2024-09-11
AU2019226487B2 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
CL2021000028A1 (es) Anticuerpo multiespecifico (divisional de solicitud 937-2020).
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MX2024006412A (es) Secuenciacion de acido nucleico usando reactivos de afinidad.
CY1123642T1 (el) Αντισωματα enanti-pd-1
MY201516A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
AR053370A1 (es) Anticuerpos anti-il-6 composiciones , metodos y usos
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
EA201691478A1 (ru) Новый полисахарид и его применения
MX2019004690A (es) Constructos de anticuerpos.
MX2024009272A (es) Constructos de anticuerpos de acidos nucleicos optimizados.
CY1123403T1 (el) Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων
BR112017013956A8 (pt) proteínas de fusão de citocinas
WO2015023461A3 (en) Influenza nucleic acid molecules and vaccines made therefrom
CY1125552T1 (el) Μεθοδος για την παρασκευη ουσιαστικα διαστερεομερικως καθαρου φωσφοροδιαμιδικου ολιγομερους, φωσφοροδιαμιδικου ολιγομερους που παρασκευαζεται με τετοια μεθοδο και φαρμακευτικη συνθεση αποτελουμενη απο τετοιο φωσφοροδιαμιδικο ολιγομερες
CY1125681T1 (el) Εμβολια κατα του ιου της γριπης και χρησεις αυτων
AR067830A1 (es) Proteinas streptococcus inmunogenicas
MX377258B (es) Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria.
CO2021007863A2 (es) Vacuna conjugada polisacárido-proteína neumocócica multivalente
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
MX2019005499A (es) Atenuacion de virulencia bacteriana mediante atenuacion de transporte de folato bacteriano.
BR112021026364A2 (pt) Antígenos de câncer e métodos
JOP20190038B1 (ar) تركيب اقتراني من السكر المتعدد لكبسولة بكتيريا المكورات الرئوية وبروتين حامل واستخداماته
CL2022001481A1 (es) Composiciones de ácidos nucleicos
BR112022017316A2 (pt) Vacina para proteção contra streptococcus suis de sorotipo 9, sequência tipo 16